



Proposed modification of the eighth edition of the AJCC-ypTNM staging system of esophageal squamous cell cancer treated with neoadjuvant chemotherapy: Unification of the AJCC staging...

Oshikiri, Taro ; Goto, Hironobu ; Kato, Takashi ; Sawada, Ryuichiro ; Harada, Hitoshi ; Urakawa, Naoki ; Hasegawa, Hiroshi ; Kanaji, Shingo ...

(Citation)

European Journal of Surgical Oncology, 48(8):1760-1767

(Issue Date)

2022-08

(Resource Type)

journal article

(Version)

Accepted Manuscript

(Rights)

© 2022 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology.

This manuscript version is made available under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International license.

(URL)

<https://hdl.handle.net/20.500.14094/0100477399>



Supplemental table. Demographic and clinical characteristics of patients in training cohort and test cohort

Patients treated with neoadjuvant therapy			
	Training data (n=234)	Test data (n=70)	P
Gender	205/29	58/12	N.S.
male/female	(87/13)	(83/17)	
Age	68 (41-82)	68 (44-82)	N.S.
Tumor location	40/105/89	12/31/27	N.S.
upper/middle/lower	(17/45/38)	(17/44/39)	
ypT-category*	9/76/27/118/4	2/23/6/37/2	N.S.
ypT0/T1/T2/T3/T4	(4/32/12/50/2)	(3/33/9/52/3)	
ypN-category*	86/77/43/28	25/25/14/6	N.S.
ypN0/N1/N2/N3	(37/33/18/12)	(36/36/20/8)	
ypM category*	213/21	64/7	N.S.
ypM0/M1	(91/9)	(90/10)	
Thoracic procedure	224/10	70/0	N.S.
thoracoscopy/Open	(96/4)	(100/0)	
Lymph node dissection	128/106	44/26	N.S.
two-field/three-field	(55/45)	(63/37)	
Residual tumor			N.S.
Negative / circumferential margin positive /	201/16/17	61/5/4	
longitudinal margin positive	(86/7/7)	(87/7/6)	

*AJCC-ypTNM 8th

CF: cisplatin/5-fluorouracil

DCF: CF with additional Docetaxel